BSE Live
Oct 24, 16:01Prev. Close
885.50
Open Price
886.05
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 24, 15:56Prev. Close
886.65
Open Price
887.80
Bid Price (Qty.)
876.40 (15)
Offer Price (Qty.)
0.00 (0)
| Balance Sheet of Cohance Lifesciences (in Rs. Cr.) | Mar 20 | Mar 19 | |
| 12 mths | 5 mths | ||
| EQUITIES AND LIABILITIES | |||
| SHAREHOLDER'S FUNDS | |||
| Equity Share Capital | 12.73 | 12.73 | |
| Total Share Capital | 12.73 | 12.73 | |
| Reserves and Surplus | 770.10 | 577.56 | |
| Total Reserves and Surplus | 770.10 | 577.56 | |
| Total Shareholders Funds | 782.83 | 590.29 | |
| NON-CURRENT LIABILITIES | |||
| Long Term Borrowings | 91.25 | 0.00 | |
| Deferred Tax Liabilities [Net] | 27.60 | 29.17 | |
| Other Long Term Liabilities | 0.51 | 0.00 | |
| Long Term Provisions | 8.31 | 5.95 | |
| Total Non-Current Liabilities | 127.68 | 35.12 | |
| CURRENT LIABILITIES | |||
| Short Term Borrowings | 94.04 | 82.79 | |
| Trade Payables | 71.06 | 53.57 | |
| Other Current Liabilities | 32.77 | 19.58 | |
| Short Term Provisions | 2.52 | 1.66 | |
| Total Current Liabilities | 200.38 | 157.61 | |
| Total Capital And Liabilities | 1,110.88 | 783.02 | |
| ASSETS | |||
| NON-CURRENT ASSETS | |||
| Tangible Assets | 353.06 | 268.21 | |
| Intangible Assets | 3.68 | 2.69 | |
| Capital Work-In-Progress | 101.71 | 111.07 | |
| Other Assets | 0.00 | 0.00 | |
| Fixed Assets | 458.45 | 381.97 | |
| Non-Current Investments | 245.65 | 0.07 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.06 | 0.07 | |
| Other Non-Current Assets | 15.20 | 11.17 | |
| Total Non-Current Assets | 719.35 | 393.28 | |
| CURRENT ASSETS | |||
| Current Investments | 30.67 | 7.06 | |
| Inventories | 174.87 | 157.10 | |
| Trade Receivables | 117.20 | 147.50 | |
| Cash And Cash Equivalents | 13.96 | 12.90 | |
| Short Term Loans And Advances | 0.20 | 0.11 | |
| OtherCurrentAssets | 54.63 | 65.07 | |
| Total Current Assets | 391.53 | 389.73 | |
| Total Assets | 1,110.88 | 783.02 | |
| OTHER ADDITIONAL INFORMATION | |||
| CONTINGENT LIABILITIES, COMMITMENTS | |||
| Contingent Liabilities | 78.83 | 10.84 | |
| CIF VALUE OF IMPORTS | |||
| Raw Materials | 0.00 | 0.00 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | |
| Capital Goods | 0.00 | 0.00 | |
| EXPENDITURE IN FOREIGN EXCHANGE | |||
| Expenditure In Foreign Currency | 0.00 | 0.00 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | |||
| Dividend Remittance In Foreign Currency | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | |||
| FOB Value Of Goods | -- | -- | |
| Other Earnings | -- | -- | |
| BONUS DETAILS | |||
| Bonus Equity Share Capital | -- | -- | |
| NON-CURRENT INVESTMENTS | |||
| Non-Current Investments Quoted Market Value | -- | -- | |
| Non-Current Investments Unquoted Book Value | 245.65 | 0.07 | |
| CURRENT INVESTMENTS | |||
| Current Investments Quoted Market Value | -- | -- | |
| Current Investments Unquoted Book Value | 30.67 | 7.06 |
12.06.2025
Cohance Life Standalone March 2025 Net Sales at Rs 330.17 crore, up 35.58% Y-o-Y
04.03.2025
Suven Pharma Consolidated December 2024 Net Sales at Rs 307.15 crore, up 39.73% Y-o-Y
28.11.2024
Suven Pharma Consolidated September 2024 Net Sales at Rs 257.72 crore, up 11.54% Y-o-Y
14.11.2024
Suven Pharma Standalone September 2024 Net Sales at Rs 236.06 crore, up 5.09% Y-o-Y